280 related articles for article (PubMed ID: 32356859)
1. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.
Roose E; Schelpe AS; Tellier E; Sinkovits G; Joly BS; Dekimpe C; Kaplanski G; Le Besnerais M; Mancini I; Falter T; Von Auer C; Feys HB; Reti M; Rossmann H; Vandenbulcke A; Pareyn I; Voorberg J; Greinacher A; Benhamou Y; Deckmyn H; Fijnheer R; Prohászka Z; Peyvandi F; Lämmle B; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
Blood; 2020 Jul; 136(3):353-361. PubMed ID: 32356859
[TBL] [Abstract][Full Text] [Related]
2. Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP.
De Waele L; Curie A; Kangro K; Tellier E; Kaplanski G; Männik A; Tersteeg C; Joly BS; Coppo P; Veyradier A; De Meyer SF; Roose E; Vanhoorelbeke K
Blood Adv; 2021 Nov; 5(21):4480-4484. PubMed ID: 34559219
[TBL] [Abstract][Full Text] [Related]
3. Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
Roose E; Vidarsson G; Kangro K; Verhagen OJHM; Mancini I; Desender L; Pareyn I; Vandeputte N; Vandenbulcke A; Vendramin C; Schelpe AS; Voorberg J; Azerad MA; Gilardin L; Scully M; Dierickx D; Deckmyn H; De Meyer SF; Peyvandi F; Vanhoorelbeke K
Thromb Haemost; 2018 Oct; 118(10):1729-1742. PubMed ID: 30235483
[TBL] [Abstract][Full Text] [Related]
4. ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura.
Sakai K; Matsumoto M; De Waele L; Dekimpe C; Hamada E; Kubo M; Tersteeg C; De Meyer SF; Vanhoorelbeke K
Blood Adv; 2023 Jan; 7(1):131-140. PubMed ID: 36306339
[TBL] [Abstract][Full Text] [Related]
5. Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity.
Ercig B; Arfman T; Hrdinova J; Wichapong K; Reutelingsperger CPM; Vanhoorelbeke K; Nicolaes GAF; Voorberg J
J Biol Chem; 2021 Oct; 297(4):101132. PubMed ID: 34461090
[TBL] [Abstract][Full Text] [Related]
6. Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen.
Dekimpe C; Roose E; Tersteeg C; Joly BS; Dewaele A; Horta S; Pareyn I; Vandenbulcke A; Deckmyn H; Feys HB; Tellier E; Kaplanski G; Scully M; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
J Thromb Haemost; 2020 Apr; 18(4):985-990. PubMed ID: 31989742
[TBL] [Abstract][Full Text] [Related]
7. ADAMTS-13 conformation influences autoimmune recognition in immune thrombotic thrombocytopenic purpura.
Underwood MI; Thomas MR; Scully MA; Crawley JTB
J Thromb Haemost; 2024 Apr; 22(4):1069-1079. PubMed ID: 38160729
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.
Sui J; Cao W; Halkidis K; Abdelgawwad MS; Kocher NK; Guillory B; Williams LA; Gangaraju R; Marques MB; Zheng XL
Blood Adv; 2019 Dec; 3(24):4177-4186. PubMed ID: 31856267
[TBL] [Abstract][Full Text] [Related]
9. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
Mazepa MA; Park YA; Raval JS
Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.
Velásquez Pereira LC; Roose E; Graça NAG; Sinkovits G; Kangro K; Joly BS; Tellier E; Kaplanski G; Falter T; Von Auer C; Rossmann H; Feys HB; Reti M; Prohászka Z; Lämmle B; Voorberg J; Coppo P; Veyradier A; De Meyer SF; Männik A; Vanhoorelbeke K
J Thromb Haemost; 2021 Feb; 19(2):478-488. PubMed ID: 33171004
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura.
Underwood MI; Alwan F; Thomas MR; Scully MA; Crawley JTB
J Thromb Haemost; 2023 Jun; 21(6):1544-1552. PubMed ID: 36813118
[TBL] [Abstract][Full Text] [Related]
12. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.
Jestin M; Benhamou Y; Schelpe AS; Roose E; Provôt F; Galicier L; Hié M; Presne C; Poullin P; Wynckel A; Saheb S; Deligny C; Servais A; Girault S; Delmas Y; Kanouni T; Lautrette A; Chauveau D; Mousson C; Perez P; Halimi JM; Charvet-Rumpler A; Hamidou M; Cathébras P; Vanhoorelbeke K; Veyradier A; Coppo P;
Blood; 2018 Nov; 132(20):2143-2153. PubMed ID: 30201758
[TBL] [Abstract][Full Text] [Related]
13. Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.
Kangro K; Roose E; Joly BS; Sinkovits G; Falter T; von Auer C; Rossmann H; Reti M; Voorberg J; Prohászka Z; Lämmle B; Coppo P; Veyradier A; De Meyer SF; Männik A; Vanhoorelbeke K
Blood Adv; 2021 Sep; 5(17):3427-3435. PubMed ID: 34495312
[TBL] [Abstract][Full Text] [Related]
14. Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.
Yue C; Su J; Fan X; Song L; Jiang W; Xia J; Shi T; Zhang X; Li X
Orphanet J Rare Dis; 2020 Aug; 15(1):225. PubMed ID: 32859237
[TBL] [Abstract][Full Text] [Related]
15. ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.
Halkidis K; Zheng XL
J Thromb Haemost; 2022 Oct; 20(10):2197-2203. PubMed ID: 35842925
[TBL] [Abstract][Full Text] [Related]
16. Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study.
Schieppati F; Russo L; Marchetti M; Barcella L; Cefis M; Gomez-Rosas P; Caldara G; Carpenedo M; D'Adda M; Rambaldi A; Savignano C; Billio A; Bruno Franco M; Toschi V; Falanga A
Am J Hematol; 2020 Aug; 95(8):953-959. PubMed ID: 32350923
[TBL] [Abstract][Full Text] [Related]
17. ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
Bonnez Q; Sakai K; Vanhoorelbeke K
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834813
[TBL] [Abstract][Full Text] [Related]
18. Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan.
Kubo M; Sakai K; Yoshii Y; Hayakawa M; Matsumoto M
Int J Hematol; 2020 Dec; 112(6):764-772. PubMed ID: 32856231
[TBL] [Abstract][Full Text] [Related]
19. Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
Basu MK; Massicano F; Yu L; Halkidis K; Pillai V; Cao W; Zheng L; Zheng XL
Thromb Haemost; 2021 Apr; 121(4):506-517. PubMed ID: 33184803
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of thrombotic thrombocytopenic purpura: easy-to-use fiber optic surface plasmon resonance immunoassays for automated ADAMTS-13 antigen and conformation evaluation.
Bonnez Q; Dekimpe C; Bekaert T; Tellier E; Kaplanski G; Joly BS; Veyradier A; Coppo P; Lammertyn J; Tersteeg C; De Meyer SF; Vanhoorelbeke K
J Thromb Haemost; 2024 Jul; 22(7):1936-1946. PubMed ID: 38554935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
